Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Apr 12, 2018
The Company will host a live conference call on Friday, May 4, 2018 at 8:30 a.m. ET to discuss financial results from the first quarter ended March 31, 2018.
-
Apr 5, 2018
Aratana confirmed it received a notice of nomination of three director candidates for election to the Company's Board of Directors from Engaged Capital, LLC and certain of its affiliated entities.
-
Mar 13, 2018
Aratana announced its fourth quarter and full year 2017 financial results, reporting total net revenues of $10.4 million and a net loss of $15.6 million or $0.37 diluted loss per share.
-
Mar 2, 2018
The Company plans on attending Cowen and Barclays investment conferences.
-
Mar 1, 2018
Aratana announced it licensed exclusive, worldwide rights to develop and commercialize AT-019 from AskAt Inc. AT-019 is a potent and innovative EP4 receptor antagonist with potential in pain, inflammation and other indications.